Convergence Investment Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.27M | Buy |
136,384
+24,312
| +22% | +$1.42M | 1.35% | 11 |
|
|
2025
Q4 | $6.05M | Buy |
112,072
+10,712
| +11% | +$515K | 1.2% | 14 |
|
|
2025
Q3 | $4.57M | Buy |
101,360
+25,092
| +33% | +$1.17M | 1.03% | 20 |
|
|
2025
Q2 | $3.53M | Sell |
76,268
-34
| -0% | -$1.67K | 0.9% | 25 |
|
|
2025
Q1 | $4.65M | Sell |
76,302
-14,191
| -16% | -$827K | 1.29% | 17 |
|
|
2024
Q4 | $5.12M | Buy |
90,493
+6,888
| +8% | +$385K | 1.14% | 16 |
|
|
2024
Q3 | $4.33M | Buy |
+83,605
| New | +$3.92M | 1.17% | 18 |
|
|
2024
Q2 | – | Sell |
-16,614
| Closed | -$901K | – | 249 |
|
|
2024
Q1 | $901K | Buy |
16,614
+6,416
| +63% | +$327K | 0.35% | 91 |
|
|
2023
Q4 | $523K | Buy |
10,198
+1,070
| +12% | +$56.2K | 0.27% | 93 |
|
|
2023
Q3 | $530K | Buy |
9,128
+1,030
| +13% | +$63.1K | 0.31% | 89 |
|
|
2023
Q2 | $518K | Sell |
8,098
-624
| -7% | -$41.8K | 0.3% | 91 |
|
|
2023
Q1 | $604K | Sell |
8,722
-103
| -1% | -$7.26K | 0.36% | 85 |
|
|
2022
Q4 | $635K | Sell |
8,825
-1,095
| -11% | -$82.6K | 0.38% | 76 |
|
|
2022
Q3 | $705K | Sell |
9,920
-325
| -3% | -$23.6K | 0.46% | 76 |
|
|
2022
Q2 | $789K | Buy |
10,245
+1,671
| +19% | +$127K | 0.48% | 78 |
|
|
2022
Q1 | $626K | Buy |
8,574
+2,886
| +51% | +$194K | 0.32% | 90 |
|
|
2021
Q4 | $355K | Sell |
5,688
-280
| -5% | -$16.4K | 0.18% | 127 |
|
|
2021
Q3 | $353K | Buy |
5,968
+953
| +19% | +$62.8K | 0.19% | 122 |
|
|
2021
Q2 | $335K | Sell |
5,015
-292
| -6% | -$19K | 0.14% | 153 |
|
|
2021
Q1 | $335K | Sell |
5,307
-20
| -0.4% | -$1.24K | 0.15% | 138 |
|
|
2020
Q4 | $330K | Sell |
5,327
-9
| -0.2% | -$553 | 0.17% | 127 |
|
|
2020
Q3 | $322K | Sell |
5,336
-16,431
| -75% | -$989K | 0.11% | 208 |
|
|
2020
Q2 | $1.28M | Buy |
21,767
+1,988
| +10% | +$119K | 0.44% | 74 |
|
|
2020
Q1 | $1.1M | Sell |
19,779
-10,257
| -34% | -$627K | 0.48% | 63 |
|
|
2019
Q4 | $1.93M | Buy |
30,036
+9,121
| +44% | +$522K | 0.55% | 54 |
|
|
2019
Q3 | $1.06M | Buy |
+20,915
| New | +$983K | 0.3% | 128 |
|
|
2019
Q1 | – | Sell |
-17,653
| Closed | -$918K | – | 314 |
|
|
2018
Q4 | $918K | Buy |
+17,653
| New | +$948K | 0.21% | 150 |
|
|
2018
Q2 | – | Sell |
-2,863
| Closed | -$181K | – | 389 |
|
|
2018
Q1 | $181K | Sell |
2,863
-76,260
| -96% | -$4.91M | 0.02% | 296 |
|
|
2017
Q4 | $4.85M | Buy |
79,123
+3,350
| +4% | +$210K | 0.65% | 28 |
|
|
2017
Q3 | $4.83M | Sell |
75,773
-3,022
| -4% | -$176K | 0.68% | 26 |
|
|
2017
Q2 | $4.39M | Buy |
+78,795
| New | +$4.29M | 0.64% | 23 |
|
Other funds holding BMY
VCM
VPM
Convergence Investment Partners's BMY Position: Q1 2026 in Review
Convergence Investment Partners increased its Bristol-Myers Squibb (BMY) stake by 22% in Q1 2026, buying an estimated $1.42M and bringing the position to 136,384 shares worth $8.27M. The position accounts for 1.35% of the portfolio, ranked #11.
Convergence Investment Partners first reported a position in BMY in Q2 2017 and has held it in 31 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Convergence Investment Partners held 136,384 shares of Bristol-Myers Squibb worth $8.27M as of Q1 2026.
- Convergence Investment Partners bought 24,312 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.42M.
- Bristol-Myers Squibb made up 1.35% of Convergence Investment Partners's portfolio in Q1 2026, its #11 holding.
- Convergence Investment Partners first reported a position in Bristol-Myers Squibb in Q2 2017 and has held it in 31 quarters since.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.